鈴木　岳之 (スズキ　タケシ)

Suzuki, Takeshi

写真a

所属（所属キャンパス）

薬学部 薬学科 薬学教育研究センター （芝共立）

職名

教授

外部リンク
このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • 疾患と薬物治療 第10章 精神疾患.

    鈴木岳之, 藤本和子, 横田恵理子, 井澤早苗., 医歯薬出版, 東京, 2008年05月

    担当範囲: 303-328

  • 通信講座テキスト 第4講座「レセプターと薬の作用機序」.

    鈴木岳之, 藤本和子., 東京/共立薬科大学, 2006年04月

    担当範囲: 1-80

  • 新しい機能形態学−ヒトの成り立ちとその働き.

    小林静子、馬場広子、平井みどり., 東京/広川書店, 2005年06月

    担当範囲: 177-184, 339-347

  • スタンダード薬学シリーズ4 生物系薬学 Ⅰ. 生命体の成り立ち 第5章 循環系.

    鈴木岳之., 東京/東京化学同人, 2005年03月

    担当範囲: 30-33

  • 受容体(レセプター)と薬の作用機序.

    鈴木岳之, 藤本和子., 東京/共立薬科大学, 2004年09月

    担当範囲: 1-

全件表示 >>

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • An Empirical Analysis of Japan's Drug Development Lag Behind the United States

    Nakamura H., Wakutsu N., Murayama S., Suzuki T.

    Journal of Clinical Pharmacology （Journal of Clinical Pharmacology)  62 （ 7 ） 847 - 854 2022年07月

    研究論文（学術雑誌）, 共著, 査読有り,  ISSN  00912700

    　概要を見る

    The “drug lag” (ie, the approval lag for new drugs) hinders patients’ access to innovative new medicines. The drug lag was heavily debated in Japan from the late 2000s to the early 2010s. It consists of “development lag” (ie, the submission date lag for new drug applications) and “review lag” (ie, the difference in review periods). As the 2 lags have different causes and display significantly different recent trends in Japan, we focus on the development lag—in contrast with most previous literature—between Japan and the United States, based on a database we created for all new drugs from 2008 to 2018 using publicly available data sources. First, we found that Japan's development lag relative to the United States did not shrink in terms of the overall distribution rather than the median, which was the focus of most prior studies. Second, we examined the factors (product characteristics) that significantly affected the development lag and found that products that underwent multiregional clinical trials and those that were certified as “breakthrough therapies” in the United States had significantly shorter development lags with high robustness, whereas products receiving price premiums did not. Finally, we discussed the policy implications of these results. For instance, innovative new drugs that are presumed to receive price premiums require enhanced policy support for early application from the initial stages of clinical trials. It is also essential to promote information sharing regarding evaluations by foreign reviewing authorities for efficient use in the home country.

  • The effect of a synthetic estrogen, ethinylestradiol, on the herg block by e-4031

    Tamura F., Sugimoto S., Sugimoto M., Sakamoto K., Yamaguchi M., Suzuki T., Fukuda K., Ieda M., Kurokawa J.

    Biomolecules （Biomolecules)  11 （ 9 ）  2021年09月

    研究論文（学術雑誌）, 共著, 査読有り

    　概要を見る

    Inhibition of K+-conductance through the human ether-a-go-go related gene (hERG) channel leads to QT prolongation and is associated with cardiac arrhythmias. We previously reported that physiological concentrations of some estrogens partially suppress the hERG channel currents by interacting with the S6 residue F656 and increase the sensitivity of hERG blockade by E-4031. Although these studies suggested that clinically used synthetic estrogens with similar structures have the marked potential to alter hERG functions, the hERG interactions with synthetic estrogens have not been assessed. We therefore examined whether ethinylestradiol (EE2), a synthetic estrogen used in oral contraceptives, affects hERG function and blockade by drugs. Supratherapeutic concentrations of EE2 did not alter amplitudes or kinetics of the hERG currents elicited by train pulses at 20 mV (0.1 Hz). On the other hand, EE2 at therapeutic concentrations reduced the degree of hERG current suppression by E-4031. The administration of EE2 followed by E-4031 blockade reversed the current suppression, suggesting that the interaction of EE2 and E-4031 alters hERG at the drug-binding site. The effects of EE2 on hERG blockade raised the possibility that other estrogens, including synthetic estrogens, can alter hERG blockade by drugs that cause QT prolongation and ventricular arrhythmias.

  • Ramelteon modulates gamma oscillations in the rat primary motor cortex during non-REM sleep

    Yoshimoto A., Yamashiro K., Suzuki T., Ikegaya Y., Matsumoto N.

    Journal of Pharmacological Sciences （Journal of Pharmacological Sciences)  145 （ 1 ） 97 - 104 2021年01月

    研究論文（学術雑誌）, 共著, 査読有り,  ISSN  13478613

    　概要を見る

    Sleep disorders adversely affect daily activities and cause physiological and psychiatric problems. The shortcomings of benzodiazepine hypnotics have led to the development of ramelteon, a melatonin MT1 and MT2 agonist. Although the sleep-promoting effects of ramelteon have been documented, few studies have precisely investigated the structure of sleep and neural oscillatory activities. In this study, we recorded electrocorticograms in the primary motor cortex, the primary somatosensory cortex and the olfactory bulb as well as electromyograms in unrestrained rats treated with either ramelteon or vehicle. A neural-oscillation-based algorithm was used to classify the behavior of the rats into three vigilance states (e.g., awake, rapid eye movement (REM) sleep, and non-REM (NREM) sleep). Moreover, we investigated the region-, frequency- and state-specific modulation of extracellular oscillations in the ramelteon-treated rats. We demonstrated that in contrast to benzodiazepine treatment, ramelteon treatment promoted NREM sleep and enhanced fast gamma power in the primary motor cortex during NREM sleep, while REM sleep was unaffected. Gamma oscillations locally coordinate neuronal firing, and thus, ramelteon modulates neural oscillations in sleep states in a unique manner and may contribute to off-line information processing during sleep.

  • Soft Matrix Promotes Cardiac Reprogramming via Inhibition of YAP/TAZ and Suppression of Fibroblast Signatures

    Kurotsu S., Sadahiro T., Fujita R., Tani H., Yamakawa H., Tamura F., Isomi M., Kojima H., Yamada Y., Abe Y., Murakata Y., Akiyama T., Muraoka N., Harada I., Suzuki T., Fukuda K., Ieda M.

    Stem Cell Reports （Stem Cell Reports)  15 （ 3 ） 612 - 628 2020年09月

    研究論文（学術雑誌）, 共著, 査読有り,  ISSN  22136711

    　概要を見る

    © 2020 The Authors In this article, Ieda and colleagues showed that a soft matrix, which is comparable with native myocardium, efficiently promoted cardiac reprogramming. This soft matrix enhanced cardiac reprogramming via inhibition of integrin, Rho/ROCK, actomyosin, and YAP/TAZ signaling and subsequent suppression of fibroblast programs, which were activated on conventional rigid substrates, thus demonstrating that mechanotransduction plays a critical role in cardiac reprogramming.

  • A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl–Hirschman Index

    Shibata S., Fukumoto D., Suzuki T., Ozaki K.

    Therapeutic Innovation and Regulatory Science （Therapeutic Innovation and Regulatory Science)  54 （ 5 ） 1047 - 1055 2020年09月

    研究論文（学術雑誌）, 共著, 査読有り,  ISSN  21684790

    　概要を見る

    © 2020, The Drug Information Association, Inc. Background: As of 2015, the Japanese pharmaceutical market was the world’s third largest pharmaceutical market. Although previous studies have examined market differences in terms of market size and pricing policy, little is known about comparative market configurations. The present study provides a comparative analysis of pharmaceutical market configurations in Japan and five other markets. Methods: Based on data for the 100 top-selling drugs in 2014 in Japan, the United States, the United Kingdom, France, Germany, and the global market, we explored differences in market configurations using the Herfindahl–Hirschman Index, Lorenz curves, and Gini coefficients. We also investigated market trends by analyzing changes in sales, sales volume, and price. Results: The 100 top-selling drugs accounted for a lower share of the total market in Japan, France, and Germany as compared to the United States and the United Kingdom. The market deviation of the 100 top-selling drugs indicated by the Herfindahl–Hirschman Index and Gini coefficient was smallest in Japan. Sales of most of the top-100 drugs increased in all the countries studied; however, directional price changes differed by country and sales volume trend. Conclusion: Our findings showed that market deviations in Japan were relatively low compared with those in other developed countries, suggesting that some of the more beneficial drugs in other developed countries obtain relatively fewer benefits from the Japanese pharmaceutical market, and some less beneficial drugs obtained more benefits.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

  • Direct reprogramming, epigenetics, and cardiac regeneration.

    鈴木 岳之

    J Card Fail 23 ( 7 ) 552 - 557 2017年

    記事・総説・解説・論説等（学術雑誌）, 単著

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • 抗うつ薬とP2X4受容体の相互作用の比較検討.

    ○笠原由佳, 三浦麻利衣, 最上由香里, 関野祐子, 佐藤薫, 鈴木岳之.

    日本薬学会第134回年会 (熊本) , 

    2014年03月

  • Neural differentiation potentials in human embryonic stem cell lines.

    ○福本大悟, 松本拓也, 岡田洋平, 末盛博文, 中辻憲夫, 鈴木岳之, 赤松和土, 岡野栄之.

    第87回日本薬理学会年会 (仙台) , 

    2014年03月

  • 中国医薬品市場の現状と製薬企業の動向分析および今後の展開.

    ○森田和仁, 鈴木岳之.

    第57回日本薬学会関東支部大会 (東京) , 

    2013年10月

  • 新薬創出加算の獲得・継続に影響を及ぼす因子の解析.

    ○反町知希, 相川大輔, 中村洋, 鈴木岳之.

    第57回日本薬学会関東支部大会 (東京) , 

    2013年10月

  • P2X4 receptor-mediated acceleration of microglial activation is important for the L-glutamate release from activated microglia in the early stage of inflammation.

    Sato K, Fujimori K, Takaki J, Suzuki T, Sekino Y.

    Neuro2013 (京都) , 

    2013年06月

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 日本の医薬品市場の特性が日本発の新薬創出に及ぼす影響の検討

    2020年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 鈴木 岳之, 基盤研究(C), 補助金,  研究代表者

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 卒業研究１（薬学科）

    2022年度

  • 薬学演習

    2022年度

  • 看護のための薬理学

    2022年度

  • 薬学英語演習Ｕ

    2022年度

  • 英語演習（薬学科）

    2022年度

全件表示 >>

このページの先頭へ▲